🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Canada / NCT04982393
Active, not recruiting Observational

BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)

NCT04982393 · tracked via the Priya Life Science Canada tracker
Phase
Observational
Started
2021-12-13
Last updated
2026-09-08

Condition(s) studied

Primary Hyperoxaluria Type 1

Study summary

The purpose of this study is to describe the natural history and progression of patients diagnosed with PH1, and to characterize the long-term real-world safety and effectiveness of lumasiran.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Documented diagnosis of PH1, per physician's determination Exclusion Criteria: * Currently enrolled in a clinical trial for any investigational agent

Primary outcome measure(s)

Trial sites (30)

FacilityCityRegionStatus
Clinical Trial Site Phoenix Arizona
Clinical Trial Site Washington D.C. District of Columbia
Clinical Trial Site Boston Massachusetts
Clinical Trial Site Rochester Minnesota
Clinical Trial Site Cincinnati Ohio
Clinical Trial Site Pittsburgh Pennsylvania
Clinical Trial Site Dallas Texas
Clinical Trial Site Houston Texas
Clinical Trial Site Ghent Belgium
Clinical Trial Site Liège Belgium
Clinical Trial Site Hamilton Ontario
Clinical Trial Site Toronto Ontario
Clinical Trial Site Laurier Quebec
Clinical Trial Site Bordeaux France
Clinical Trial Site Lyon France
Clinical Trial Site Paris France
Clinical Trial Site Berlin Germany
Clinical Trial Site Cologne Germany
Clinical Trial Site Hamburg Germany
Clinical Trial Site Jerusalem Israel
Clinical Trial Site Orbassano Torino
Clinical Trial Site Milan Italy
Clinical Trial Site Verona Italy
Clinical Trial Site Amsterdam Netherlands
Clinical Trial Site Santa Cruz de Tenerife Canary Islands
Clinical Trial Site Barcelona Spain
Clinical Trial Site Las Palmas Spain
Clinical Trial Site Bern Switzerland
Clinical Trial Site London England
Clinical Trial Site London United Kingdom

More Alnylam Pharmaceuticals trials in Canada

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04982393 on ClinicalTrials.gov ↗ ← All trials in Canada